Literature DB >> 27152163

Peripheral actions of GPCRs in energy homeostasis: view from the Chair.

M Bouvier1.   

Abstract

The roles of G-protein-coupled receptors (GPCRs) in the control of food intake and energy expenditure are being increasingly recognized, and new drug candidates targeting these receptors are making their entry into the clinic. GPCRs exert their action along the various sites of regulation of energy homeostasis control including the central nervous system, the pancreas, the gut and fat cells. Exciting new data about GPCRs recognizing and mediating the effects of lipid mediators and concerning receptors for which no endogenous ligands have been identified yet open new exciting avenues for the validation of additional drug targets. In addition, recently developed paradigms around the concepts of cross-talk regulation and functional selectivity should lead to the development of drugs with improved therapeutic efficacy and reduced undesirable effects. Some of these promising discoveries are discussed in the present article and accompanying papers.

Entities:  

Keywords:  G-protein-coupled receptors; cross-talk regulation; functional selectivity; incretin receptors; lipid receptors; orphan receptors

Year:  2014        PMID: 27152163      PMCID: PMC4850581          DOI: 10.1038/ijosup.2014.2

Source DB:  PubMed          Journal:  Int J Obes Suppl        ISSN: 2046-2166


  11 in total

Review 1.  Seven-transmembrane receptors.

Authors:  Kristen L Pierce; Richard T Premont; Robert J Lefkowitz
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 2.  The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes.

Authors:  H Roelofsen; M G Priebe; R J Vonk
Journal:  Benef Microbes       Date:  2010-11       Impact factor: 4.205

Review 3.  Recent advances in gut nutrient chemosensing.

Authors:  C A Nguyen; Y Akiba; J D Kaunitz
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 4.  The evasive nature of drug efficacy: implications for drug discovery.

Authors:  Ségolène Galandrin; Geneviève Oligny-Longpré; Michel Bouvier
Journal:  Trends Pharmacol Sci       Date:  2007-07-19       Impact factor: 14.819

Review 5.  Restructuring G-protein- coupled receptor activation.

Authors:  Martin Audet; Michel Bouvier
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

Review 6.  Fasiglifam as a new potential treatment option for patients with type 2 diabetes.

Authors:  Kohei Kaku
Journal:  Expert Opin Pharmacother       Date:  2013-11-06       Impact factor: 3.889

Review 7.  Orphan G protein-coupled receptors and obesity.

Authors:  Yan-Ling Xu; Valerie R Jackson; Olivier Civelli
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

Review 8.  GLP-1R agonist therapy for diabetes: benefits and potential risks.

Authors:  Susan L Samson; Alan Garber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-04       Impact factor: 3.243

Review 9.  Central G-Protein Coupled Receptors (GPCR)s as molecular targets for the treatment of obesity: assets, liabilities and development status.

Authors:  Keith J Miller; Brian J Murphy; Mary Ann Pelleymounter
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-10

Review 10.  Management of type 2 diabetes: new and future developments in treatment.

Authors:  Abd A Tahrani; Clifford J Bailey; Stefano Del Prato; Anthony H Barnett
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.